肝细胞腺瘤恶性转变为肝细胞癌的基于全外体测序的突变概况
Yichao Bu1, Run Huang1,2, Jun Gao1
1Department of Liver Surgery, Zhongshan Hospital, Fudan University, Liver Cancer Institute, Fudan University, Shanghai, China.
Clinical and experimental pharmacology & physiology
|June 6, 2024
概括
这项研究揭示了肝细胞腺瘤 (HCA) 和肝细胞癌 (HCC) 具有共同的起源,但演变出不同的基因组特征. 这些发现表明有针对性治疗的潜力,以及对肝癌免疫治疗的高度敏感性.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 肝病学 肝病学是一种肝病学.
背景情况:
- 肝细胞腺瘤 (HCA) 是一种罕见的良性肝脏瘤,具有恶性转变到肝细胞癌 (HCC) 的潜力.
- 推动HCA导致HCC进展的基因组机制尚未完全理解.
- 识别这些机制对于开发有针对性的疗法至关重要.
研究的目的:
- 为了研究肝细胞腺瘤和肝细胞癌的基因组景观.
- 在恶性转变期间识别共享和独特的基因组变化.
- 探索潜在的治疗策略,包括基于免疫的疗法.
主要方法:
- 来自三名患者的HCA,HCC和相邻的正常肝脏组织的全外体测序 (WES).
- 实体变异调用,复制数变异 (CNV) 分析,克隆性评估和突变特征分析.
- 非负矩阵因子化和家族遗传树构造.
主要成果:
- 在患者病例中观察到的基因组异质性,但在同一瘤的HCA和HCC组织中存在类似的突变格局.
- 识别参与HCA-HCC转变的共享和独特的突变特征和途径.
- 证据表明HCA和HCC的共同单克隆起源,在瘤中具有显著的遗传多样性.
- 与免疫疗法相关的标志物升高,表明对免疫疗法的潜在敏感性.
结论:
- HCA和HCC有共同的起源,但呈现出不同的进化基因组路径.
- 了解这些途径为阻止恶性转变提供了潜在的治疗点.
- 免疫标志物升高表明基于免疫的疗法在治疗肝脏恶性瘤方面发挥了有希望的作用.
更多相关视频
09:27Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish
Published on: April 1, 2021
3.5K
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
5.2K
相关概念视频
Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
